Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitors.
Shuttleworth SJ, Silva FA, Cecil AR, Tomassi CD, Hill TJ, Raynaud FI, Clarke PA, Workman P.
Curr Med Chem. 2011, 18(18), p2686-714.

Progress in the development of small molecule therapeutics targeting Th17 cell function for the treatment of immune-inflammatory diseases.
Shuttleworth S, Townsend P, Silva F, Cecil A, Hill T, Tomassi C, Rogers H, Harrison R.
Prog Med Chem. 2011, 50, p109-33.

Histone Deacetylase inhibitors: new promise in the treatment of immune and inflammatory diseases.
Shuttleworth SJ, Bailey SG, Townsend PA.
Curr Drug Targets. 2010, 11(11), p1430-8.

Progress in the design and development of phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of chronic diseases.
Shuttleworth S, Silva F, Tomassi C, Cecil A, Hill T, Rogers H, Townsend P.
Prog Med Chem. 2009, 48, p81-131.